Wockhardt Limited has informed the Exchange about Credit Rating

Rating UpgradedCredit & Debt View source PDF Explain this filing

WOCKPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.3%Reaction day

₹1477.00

prior close

₹1471.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.1%-2.2% vs market

Pharmaceuticals peers, median of 148sector-1.0%-2.3% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Smallcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-1.2

15m

-1.5

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.3-1.1-2.2-1.0-2.3

Next day

-3.5-1.4-2.0-1.0-2.5

-3.8-0.0-3.8-0.1-3.8

-4.4+0.6-5.0-0.3-4.1

+0.6+1.4-0.8+0.8-0.2

-0.1+0.7-0.9+0.0-0.2

-1.1+1.1-2.2+0.4-1.5

15d

+3.5+4.4-0.9+1.8+1.7

+4.4-0.5+4.9-2.1+6.5

-12.3+3.6-15.9-2.2-10.1

-16.4-0.1-16.3-5.2-11.2

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

ICRA Limited has upgraded Wockhardt's credit ratings across all instruments and revised the outlook from 'Stable' to 'Positive'. The long-term fund-based term loan rating moved up from BBB- (Stable) to BBB (Positive), and short-term ratings improved from A3 to A3+. The upgrade reflects sustained growth in earnings, cash flows, and operating profit margins, along with an improved financial profile, better liquidity, and stronger debt protection measures. ICRA also cited Wockhardt's healthy market position in India, Europe, and emerging markets, and the launch of its new drug Miqnaf® as supporting factors.

Likely market impact

This is a positive signal for shareholders, indicating improved financial health and lower borrowing costs going forward. A credit rating upgrade typically boosts investor confidence and may support a positive sentiment around the stock.